Tarsus's XDEMVY hits $194.6M as $632.2M of acquired IPR&D drives a $668.3M loss

The quarter in numbers

Tarsus Pharmaceuticals reported third-quarter 2026 net product sales of $194.6 million, against $118.7 million in the same period of 2025. The company described this as a record for XDEMVY and an increase of approximately 64% year over year. Year-to-date net product sales reached $513.9 million, compared with $299.7 million in the first nine months of 2025.

The bottom line looks very different. Net loss was $668.3 million, or $(14.40) per basic and diluted share, versus a loss of $12.6 million, or $(0.30) per share, a year earlier. Year-to-date net loss was $693.9 million, or $(15.67) per share, compared with $58.0 million, or $(1.40) per share. The release attributes the swing largely to one line item, covered below.

What drove sales

The company said sales growth came from higher volume and improvements in gross-to-net discounts. It did not quantify the split between the two, and it gave no regional breakdown. XDEMVY is described as the first and only FDA-approved treatment for Demodex blepharitis (DB).

The release offers several demand indicators. The company said the average number of eye care professionals prescribing XDEMVY at least daily rose approximately 20% from the start to the end of the quarter, which it characterised as a seasonally softer period in prescription eye care. It also said direct-to-consumer initiatives drove a 75% increase in high-value actions, with higher prescription conversion than last year.

Refills accounted for approximately 20% of XDEMVY prescriptions in the quarter. The company said retreatment is becoming a more established part of care. Tarsus also said more than one million bottles have been dispensed and cumulative net product sales have passed $1 billion since launch.

Costs, margins and the acquisition charge

Cost of sales was $13.9 million versus $8.3 million, and the company said gross margin was consistent at approximately 93% in both periods. It cited XDEMVY manufacturing costs, the royalty on net sales and amortisation of milestone payments to its licensor.

The decisive item was acquired in-process R&D expense of $632.2 million, made up of $81.0 million for iRenix (IRX-101) and $551.2 million for Alkeus (gildeuretinol). The company said these were expensed because the assets have no alternative future use, and there was no comparable charge in the prior-year quarter. The charge is of a size that accounts for nearly all of the quarter's net loss.

Operating spending also rose. R&D was $44.2 million versus $16.3 million; of the $27.9 million increase, $13.7 million related to Alkeus, including $3.0 million of acquired inventory. The remainder reflected $6.8 million for the TP-05 Calliope trial, $1.8 million for TP-04 and $0.8 million for IRX-101, partly offset by a $1.1 million decline in TP-03 spending. SG&A was $168.0 million versus $108.6 million, including $29.8 million tied to Alkeus, of which $23.5 million was transaction and integration cost. Excluding Alkeus, the company cited $11.7 million more in commercial and marketing spend, including DTC advertising, $9.6 million for patient support, IT, legal and professional services, and $8.3 million of added payroll.

Stock-based compensation grew as well: $10.2 million in R&D (versus $3.0 million) and $16.8 million in SG&A (versus $9.1 million). A $1.6 million decrease in the fair value of Alkeus-related contingent consideration was also recorded.

Balance sheet and guidance

Cash, cash equivalents and marketable securities were $309.6 million at September 30, 2026. The release does not provide a comparison figure or describe how the acquisitions were funded, so the liquidity trend cannot be assessed from this document alone.

The release as provided contains no financial guidance, whether for revenue, expenses or profitability. The only forward-looking commitments are clinical and regulatory timelines. Investors and competitors seeking a view on spending intensity after the acquisitions will have to look to the same-day conference call, details of which are not in the release.

Pipeline and catalysts

The acquisitions broaden Tarsus beyond lotilaner. The company said it has the potential to bring five medicines to patients in the next five years. The timelines it set out are:

TP-04 (lotilaner gel, ocular rosacea): Phase 2 Kore topline data expected in the first half of 2027. TP-05 (oral lotilaner, Lyme disease prevention): Calliope Phase 2 enrollment complete, topline expected in the first half of 2027, anticipated to support a Phase 3-ready package. IRX-101 (ocular antiseptic for intravitreal injections): Phase 3 Comfort study to start in the first half of 2027, topline in 2028. Gildeuretinol (Stargardt disease): global Phase 3 Northstar enrolling, topline expected in 2029. The company noted Stargardt has no FDA-approved treatment.

The company also appointed Neera Clase as Chief Commercial Officer.

What to watch next

First, whether volume-led growth holds as the company's seasonal comment implies it should, and whether refill share, now approximately 20% of prescriptions, keeps rising. Second, the cost base: SG&A and R&D both grew sharply even before the Alkeus effects, and integration costs may recur. Third, the first-half 2027 cluster of Kore and Calliope readouts and the Comfort start, which will test the diversification story. Finally, any quantified guidance or disclosure on funding and cash use that Tarsus provides beyond this release.